In this randomized clinical trial that included 32 adults with type 2 diabetes requiring initiation or adjustment of basal insulin, participants who used a voice-based conversational AI application had a significantly improved time to optimal insulin dose (median, 15 days vs >56 days) and insulin adherence (83% vs 50%) compared with participants receiving standard of care. This evidence concerns the gene INS and type 2 diabetes mellitus.